Gamma-interferon (IFN-γ) detection is an in vitro laboratory technique that quantifies the release of IFN-γ from T lymphocytes following antigen-specific stimulation, providing a reliable measure of cell-mediated immunity. It is best known as the analytical foundation of interferon-gamma release assays (IGRAs) used for latent tuberculosis infection screening, and it also supports immune function evaluation, infectious disease diagnosis, and immunology research. This article provides a comprehensive technical overview of IFN-γ detection, covering test principles, sample types, testing items, analytical methods, clinical applications, and frequently asked questions.
Technical Overview
Interferon-gamma (IFN-γ, type II interferon) is a homodimeric glycoprotein cytokine encoded on chromosome 12 and produced primarily by Th1 CD4+ T lymphocytes, CD8+ cytotoxic T cells, and natural killer (NK) cells. As a key effector molecule of cell-mediated immunity, IFN-γ activates macrophages, enhances antigen presentation through major histocompatibility complex (MHC) expression, and coordinates the host defense against intracellular pathogens such as Mycobacterium tuberculosis.
The core principle of IFN-γ detection is ex vivo antigen stimulation: patient blood cells are incubated with specific antigens (for example, the M. tuberculosis-specific peptides ESAT-6 and CFP-10). If the patient's memory T cells have been previously sensitized to these antigens, they release IFN-γ into the culture supernatant or produce spot-forming colonies on antibody-coated membranes. Because the genes encoding ESAT-6 and CFP-10 are absent from Mycobacterium bovis BCG and most environmental mycobacteria, the resulting interferon-gamma release assay (IGRA) offers high specificity for tuberculosis infection. Beyond tuberculosis, quantitative IFN-γ measurement is widely applied in immunology research, immune competence monitoring, vaccine evaluation, and cytokine profiling.
Testing Samples
Whole Blood
Heparinized or anticoagulant-treated whole blood is the standard specimen for IGRAs. For assays such as QuantiFERON-TB Gold Plus, blood is collected directly into specialized tubes pre-coated with test antigens and controls, then incubated at 37°C for 16–24 hours before plasma separation and measurement of released IFN-γ. Prompt incubation (ideally within a few hours of collection) is critical to preserve lymphocyte viability and responsiveness.
Plasma
Plasma harvested after antigen stimulation is the actual analyte measured in ELISA- or chemiluminescence-based IGRAs. Standard collection tubes with lithium heparin or EDTA may be used for research-grade cytokine quantification, provided that processing and freezing conditions are strictly controlled.
Serum
Serum can be used for direct measurement of circulating IFN-γ levels in cytokine profiling panels, although circulating concentrations are often very low and near the detection limit of standard assays, which limits clinical interpretability.
Peripheral Blood Mononuclear Cells (PBMCs)
Isolated PBMCs are the preferred specimen for ELISpot-based methods such as T-SPOT.TB and for research applications. PBMCs are washed, counted, and plated at a standardized density before stimulation, which improves sensitivity in immunocompromised patients where lymphopenia may otherwise reduce assay performance.
Body Fluids
Cerebrospinal fluid, pleural fluid, peritoneal fluid, and bronchoalveolar lavage fluid may be tested in selected contexts, particularly as adjunctive evidence in suspected tuberculous meningitis or pleuritis. Local IFN-γ production can provide diagnostic information that serum-based testing cannot.
Culture Supernatants
In research settings, supernatants from stimulated cell cultures (T cell stimulation assays, dendritic cell–T cell co-cultures, or drug hypersensitivity studies) are routinely analyzed to characterize antigen-specific T cell responses.
Testing Items
Depending on the clinical or research objective, IFN-γ detection encompasses the following measurable items:
- Quantitative IFN-γ concentration in plasma, serum, or culture supernatant, reported in IU/mL or pg/mL.
- Negative (nil) control value, representing background IFN-γ production in the absence of antigen stimulation.
- Antigen-stimulated IFN-γ response, using M. tuberculosis-specific peptide antigens (ESAT-6, CFP-10) or other target antigens of interest.
- Mitogen-positive control response, using phytohemagglutinin (PHA) or other mitogens to confirm T cell competence and validate the assay.
- IGRA interpretation, typically calculated as antigen-stimulated value minus nil value and interpreted against manufacturer-defined cutoffs.
- Spot-forming units (SFUs) in ELISpot-based assays, representing the number of IFN-γ-secreting cells per fixed number of PBMCs.
- Indeterminate result assessment, triggered by excessive background (high nil) or insufficient mitogen response, indicating an invalid test requiring repetition.
Testing Methods
Enzyme-Linked Immunosorbent Assay (ELISA)
Sandwich ELISA is the most common platform for quantitative IFN-γ measurement. Capture antibodies immobilized on microplate wells bind IFN-γ in the sample, and a detection antibody–enzyme conjugate generates a colorimetric signal proportional to IFN-γ concentration. Results are derived from a standard curve. ELISA is simple, cost-effective, and amenable to high-throughput screening, with a typical analytical sensitivity in the low pg/mL range.
Enzyme-Linked Immunospot Assay (ELISpot)
ELISpot detects individual IFN-γ-secreting cells. PBMCs are cultured on membranes coated with anti-IFN-γ antibodies; cytokine secreted by each activated T cell is captured locally and visualized as a discrete spot after development. Each spot corresponds to one antigen-reactive cell, providing single-cell sensitivity that is approximately an order of magnitude more sensitive than ELISA. This is the principle of the T-SPOT.TB assay, which reports results as spot counts against a defined threshold.
Chemiluminescence Immunoassay (CLIA)
CLIA replaces the colorimetric substrate of ELISA with a chemiluminescent label, substantially improving analytical sensitivity and dynamic range. Automated CLIA platforms enable rapid turnaround, standardized processing, and direct plasma IFN-γ quantification, making them increasingly popular in high-volume clinical laboratories.
Flow Cytometry with Intracellular Cytokine Staining (ICS)
After stimulation in the presence of secretion inhibitors such as brefeldin A, cells are permeabilized and stained with fluorescent anti-IFN-γ antibodies. Multiparameter flow cytometry identifies the exact IFN-γ-producing subsets (CD4+, CD8+, NK cells) and can be combined with phenotypic markers. This method is mainly used in research and vaccine immunogenicity studies.
QuantiFERON-TB Gold Plus (QFT-Plus)
A tube-based ELISA or CLIA IGRA using ESAT-6/CFP-10 peptide cocktails in two antigen tubes designed to stimulate both CD4+ and CD8+ T cells, alongside nil and mitogen control tubes. The result is interpreted from the antigen-minus-nil IFN-γ value with a cutoff of 0.35 IU/mL (or equivalent per platform).
T-SPOT.TB
An ELISpot-based IGRA in which a standardized number of PBMCs is stimulated with separate ESAT-6 and CFP-10 peptide pools. Positive results are reported when spot counts exceed the threshold (commonly 8 spots above the nil control), with a borderline category around the cutoff to account for analytical variability.
Applications
Gamma-interferon detection is applied across a broad spectrum of clinical and research scenarios:
- Screening for latent tuberculosis infection (LTBI) in close contacts of active TB cases, healthcare workers, prisoners, and immigrants from high-burden regions.
- Pre-treatment LTBI testing before initiation of tumor necrosis factor (TNF) inhibitors, biologics, immunosuppressants, or organ transplantation.
- Auxiliary diagnosis of active tuberculosis, especially extrapulmonary TB (tuberculous meningitis, pleuritis, peritonitis) and pediatric TB, where microbiological confirmation is difficult.
- Occupational health surveillance programs with serial testing of healthcare personnel.
- Differentiation of TB infection from BCG-vaccination-related tuberculin skin test positivity, since ESAT-6/CFP-10 antigens are absent from BCG strains.
- Assessment of cell-mediated immune competence in immunodeficiency workups, post-transplant monitoring, and HIV management.
- Immunogenicity evaluation of vaccines targeting intracellular pathogens.
- Research applications including Th1/Th2 polarization studies, cytokine profiling, T cell epitope mapping, and drug hypersensitivity (T cell-mediated adverse reaction) investigation.
FAQ
Can an IFN-γ release assay distinguish latent from active tuberculosis?
No. IGRAs detect the presence of an immune response to M. tuberculosis antigens but cannot differentiate latent infection from active disease. Diagnosis of active TB requires microbiological, molecular (e.g., nucleic acid amplification), radiological, and clinical evaluation; IGRA results should always be interpreted together with exposure history and other findings.
Does BCG vaccination affect the result?
BCG vaccination has minimal impact on IGRA results because the RD1-region-encoded antigens ESAT-6 and CFP-10 are deleted from all BCG strains. This represents a major advantage over the tuberculin skin test in BCG-vaccinated populations, although repeated or recent BCG vaccination may rarely cause nonspecific effects.
What does a positive result mean?
A positive result indicates that the patient's T cells respond to M. tuberculosis-specific antigens, suggesting infection with M. tuberculosis (either latent or active). It is not proof of active disease and should be followed by clinical and diagnostic evaluation to exclude active TB before considering preventive treatment.
Why do indeterminate or invalid results occur?
Indeterminate results typically arise from an elevated nil (background) response or a failed mitogen-positive control. Common contributing factors include immunosuppression (HIV infection, corticosteroids, biologics), lymphopenia, lymphocyte dysfunction, improper sample handling, delayed incubation, or hemolysis. The test should be repeated, ideally with a freshly collected specimen or using the PBMC-based ELISpot format.
What are the sensitivity and specificity of IGRAs?
Pooled specificity for both major commercial IGRAs typically exceeds 95% in low-risk, BCG-vaccinated populations. Sensitivity for confirmed active TB is approximately 80–90%, with ELISpot methods retaining somewhat better performance in immunocompromised and pediatric populations. Performance varies by study design, population, and reference standard.
What sample handling precautions are required?
For tube-based assays, blood must be collected in the correct order, mixed thoroughly, and incubated at 37°C within the manufacturer-specified time window (commonly within 8–16 hours of collection, depending on the platform). Specimens should never be refrigerated before incubation, and plasma can be stored refrigerated or frozen after separation until measurement.
How often should serial testing be performed?
For occupational screening, serial testing is usually performed annually or according to institutional policy. Conversions (negative to positive) and reversions can occur due to biological and analytical variability near the cutoff, so borderline or unexpected results warrant repeat testing and clinical correlation.